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Abstract
Background: Sparse relative effectiveness evidence is a frequent problem in Health Technology Assessment (HTA).
Where evidence directly pertaining to the decision problem is sparse, it may be feasible to expand the evidence-base
to include studies that relate to the decision problem only indirectly: for instance, when there is no evidence on a
comparator, evidence on other treatments of the same molecular class could be used; similarly, a decision on children
may borrow-strength from evidence on adults. Usually, in HTA, such indirect evidence is either included by ignoring
any differences (‘lumping’) or not included at all (‘splitting’). However, a range of more sophisticated methods exists,
primarily in the biostatistics literature. The objective of this study is to identify and classify the breadth of the available
information-sharing methods.
Methods: Forwards and backwards citation-mining techniques were used on a set of seminal papers on the topic of
information-sharing. Papers were included if they specified (network) meta-analytic methods for combining
information from distinct populations, interventions, outcomes or study-designs.
Results: Overall, 89 papers were included. A plethora of evidence synthesis methods have been used for
information-sharing. Most papers (n = 79) described methods that shared information on relative treatment effects.
Amongst these, there was a strong emphasis on methods for information-sharing across multiple outcomes (n = 42)
and treatments (n = 25), with fewer papers focusing on study-designs (n = 23) or populations (n = 8). We categorise
and discuss the methods under four ’core’ relationships of information-sharing: functional, exchangeability-based,
prior-based and multivariate relationships, and explain the assumptions made within each of these core approaches.
Conclusions: This study highlights the range of information-sharing methods available. These methods often
impose more moderate assumptions than lumping or splitting. Hence, the degree of information-sharing that they
impose could potentially be considered more appropriate. Our identification of four ‘core’ methods of
information-sharing allows for an improved understanding of the assumptions underpinning the different methods.
Further research is required to understand how the methods differ in terms of the strength of sharing they impose
and the implications of this for health care decisions.
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Background
Health Technology Assessment (HTA) is the systematic
evaluation of the properties, effects and impact of health
technologies with a view to inform decision-making in
health care [1]. Regardless of whether or not a system
functions under explicit budget constraints, resources
spent could have always been used for alternative pur-
poses. Therefore, policy-makers are always faced with
difficult decisions about whether interventions should be
funded. This requires an assessment of whether the ben-
efits of an intervention are sufficient to justify the health
opportunity costs of funding it [2]. It follows that a set of
tools ought to be used so that policy-makers can rationally
and transparently decide about the adoption of a given
health technology [3].
Decision analysis provides a quantitative framework
that brings together all relevant evidence on the impact
of an intervention on health outcomes and costs, whilst
making explicit judgements about how different types
and sources of evidence are linked together (model struc-
ture) and which elements are relevant to decision-making
(reflecting social values). The outputs of a Decision Ana-
lyticModel (DAM) include incremental costs and benefits
and can be useful for decision-makers [4].
Each input within a DAM is a parameter and consti-
tutes a potential research question that can be informed
by evidence which is typically identified using litera-
ture reviews. To assist study selection when identify-
ing evidence for reviews, research questions are defined
using the PICOS framework, where P stands for Pop-
ulation, I for Intervention, C for Comparator, O for
Outcome, and S for Study-design [5]. Typically, review-
ers exclude studies deviating from the inclusion crite-
ria on any PICOS dimension; that is, they usually only
include studies providing direct evidence. Hence, direct
evidence on relative effectiveness comprises of one or
more randomised studies, evaluating the intervention(s)
under assessment, recruiting patients from the popula-
tion of interest, and measuring effects on all relevant
outcomes.
Where multiple studies exist to inform the same param-
eter, these can be synthesised to generate a single esti-
mate that represents the evidence-base. To synthesise the
evidence base and provide DAMs with relative effective-
ness inputs, standard Meta-Analysis (MA) and Network
Meta-Analysis (NMA)methods [6, 7] are commonly used.
Although synthesis is more common for Relative Treat-
ment Effects (RTEs), evidence synthesis methods can also
be applied for other DAM inputs such as costs andQuality
of Life (QoL).
However, in HTA, direct evidence may be sparse, het-
erogeneous, or limited in other ways and synthesis may
become problematic. Where evidence is sparse, it may
not be possible to obtain the required Relative Treatment
Effect (RTE) estimates, and even when they can be ob-
tained, they may be highly uncertain and may not be
robust due to assumptions imposed in the analysis [8, 9].
Evidence sparsity may also prevent appropriate explo-
ration of heterogeneity because small studies are at higher
risk of enrolling unrepresentative populations [10] and
provide less evidence to enable robust subgroup analyses.
A policy relevant alternative to limited or sparse data
may be to extend the evidence base beyond the direct
evidence. A topical example concerns paediatric indica-
tions for which the evidence-base is typically sparse due to
the regulatory restrictions on trials. To support decision-
making for this population, the Food and Drugs Admin-
istration (FDA) [11] and the European Medicines Agency
(EMA) now propose that “The evidence needed to address
the research questions that are important for marketing
authorisation of a given product in the target popula-
tion might be modified based on what is known for other
populations” [12]. Whilst in the aforementioned example
the evidence is extended to consider another population,
in principle, indirect evidence may relate to any other
dimension of PICOS (Fig. 1) —it may include studies
assessing a different, but related, treatment or pertaining
to a different study-design than what is specified in the
research question. Note that, in this context, NMA also
considers indirect evidence, pertaining to other treatment
comparisons i.e. indirect evidence on the ‘Intervention’
PICOS dimension, to inform the treatment effect(s) of
primary interest [13].
Within a decision-making context, the use of indirect
evidence, as long as it is judged relevant, contributes to
accountability by allowing for all relevant evidence to be
considered. Combining all relevant sources of evidence
may yield more precise estimates than the direct evidence
alone and allow better characterisation of heterogeneity
and uncertainty. However, when indirect evidence are not
sufficiently relevant or of high-quality, using indirect evi-
dence may also introduce bias and inflate heterogeneity
estimates.
The use of indirect evidence to support decision-
making is not exclusive to the aforementioned regulatory
context and has permeated HTA processes. Examples
can be found in Technology Appraisals (TAs) conducted
by the National Institute for Health and Care Excel-
lence (NICE) to inform routine use of technologies in the
National Health Service (NHS) in England andWales. For
instance, TA445 [14] considered adult studies to com-
plement a sparse paediatric evidence base. Also, relative
effectiveness has been generalised across subgroups of dif-
ferent Hepatitis C genotypes [15]. These two examples use
indirect evidence by considering both sources perfectly
generalisable (‘lumping’), as an alternative to being con-
sidered completely independent (‘splitting’). There are,
however, examples of appraisals which use indirect evi-
Nikolaidis et al. BMCMedical ResearchMethodology          (2021) 21:107 Page 3 of 13
Fig. 1 An illustration of the extended evidence base. The small pie in the middle, characterised by P0 , I0 , C0 ,O0 , S0 , represents only the directly
relevant information which usually comprise only a small part of the evidence that is relevant to a decision. The evidence outside the small pie
represent examples of indirectly relevant information for each of the PICOS dimensions
dence in more sophisticated ways. For instance, TA383
[16] used indirect evidence across interventions by assum-
ing a ‘class-effect‘ between treatments that function
through the same molecular pathway. TA139 [17] and
TA168 [18] simultaneously modelled two outcomes lever-
aging their correlation structure and TA244 [19] modelled
a network of interventions with multiple treatment com-
ponents assuming that the relative effect of an interven-
tion is the sum of the relative effects of its comprising
components.
Inevitably, a judgement on whether the indirect evi-
dence is relevant is always required. However, what is
often not made explicit is that, where both direct and
indirect evidence are considered, there should be appro-
priate consideration for the extent of information-sharing
permitted by different synthesis methods (i.e. the extent
to which the indirect evidence is allowed to affect the
estimates obtained by using only the direct evidence).
The objective of this review is to identify information-
sharing evidence synthesis methods that have been used
in the literature and improve understanding of these
methods by making explicit the fundamental assump-
tions underpinning them. We do so by identifying the
‘core’ relationships used to share information. This review
increases awareness around the breadth of available
information-sharing methods and aids transparency in
information-sharing methods choice. To our knowledge,
this topic has not been explored in the past with a clear
policy focus.
Methods
We conducted a literature search, that was systematic and
transparent in its methods and conduct, but was not com-
prehensive due to the challenges described ahead [20].
We, therefore, will refer to our methodology as a literature
review and not as a systematic review.
To inform the design and conduct of the literature
review, we initially conducted a scoping review (details
provided in Additional file 1). It’s aims were to clar-
ify working definitions, determine inclusion and exclu-
sion criteria, understand whether keyword-based meth-
ods [20] would generate a sensitive and specific search
strategy, obtain a comprehensive list of representative
seminal papers on information-sharing, and conceive how
the breadth of information-sharing methods could be cat-
egorised in a useful manner. We found that consistent
terminology was not used when referring to methods that
combined direct and indirect evidence. Therefore, for the
main literature review, we used citation-mining methods
[21] which are efficient [22] and have been used for sim-
ilar reviews [23]. The methods of the main review were
protocolled in advance.
Citation-mining involves two steps. The first encom-
passed the compilation of a list of seminal/influential
papers. All relevant papers identified in the scoping
review were considered and seminal papers were selected
to reflect breadth [22] by including different fields of
research:MA, NMA,multi-parameter evidence synthesis,
synthesis of multiple outcomes and the incorporation of
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evidence on historical controls in trial-design. Two exter-
nal evidence synthesis experts were consulted to validate
the list and provide additional references. The second,
and main, step of the citation-mining review was then
conducted in the Web of Science (WoS) on 20/Feb/2019
by identifying all the citations of the seven seminal papers
[8, 24–29], and then all articles that cited the seminal
papers — i.e. a forwards and backwards citation-mining.
Inclusion and exclusion criteria were pre-specified (see
Additional file 1). Articles were included if they formally
specified MA or NMA models (in mathematical notation
or computer code) that combined information pertain-
ing to multiple populations, interventions, outcomes or
study-designs, or if they utilised evidence from an exter-
nal source (such as a previous meta-analysis). Given the
aim of identifying a range of methods for the sharing
of information, papers that used only standard NMA
methods originally described by Lu et al. [7] (i.e. by pool-
ing evidence sets assuming perfect exchangeability) were
excluded.
Data extraction was pre-specified and included year of
publication, the synthesis challenge addressed, the spe-
cific method (relationship) imposed between the ‘direct’
and ‘indirect’ evidence to facilitate information-sharing,
the PICOS dimension(s) of indirectness, the ‘cores’
used, the parameter over which information-sharing was
imposed, and whether the paper fell into the field of MA
or NMA.When papers tackled multiple challenges simul-
taneously (e.g. [30–32]), the challenges they dealt with
were isolated and extracted separately. Further informa-
tion on the search strategy and inclusion and exclusion
criteria is provided in Additional file 1.
The search was conducted in Zotero version 5.0.69 and
a link to the included papers Zotero database, where the
papers have been grouped according to various tags, is
provided in the end of the manuscript. The PRISMA
checklist for systematic reviews is provided in Additional
file 2. The results of the search were reported descrip-
tively, by grouping the methods by the policy problem and
the PICOS dimension of indirectness. Methods were then
categorised according to the ‘core’ relationship they used
to enable information-sharing and the statistical methods
falling within each core were described.
Results
Characteristics of the included studies
The review identified 89 papers (Fig. 2) which are avail-
able in our online database (link provided in the end
of the manuscript). The majority (n = 79) described
methods that shared information on relative treatment
effects. Other studies used methods to share informa-
tion on comparison-specific meta-regression slopes (n =
4), comparison-specific between-studies heterogeneities
(n = 6), or study-specific baselines (n = 2). Overall, there
was a balance amongst papers that developed methods
within MA (n = 45) and NMA (n = 44). There was
a strong emphasis on methods for information-sharing
across multiple outcomes (42 papers) and treatments (25
papers), with fewer papers focusing on study-designs (23
papers) or populations (8 papers) (Table 1). Note that
some papers described methods sharing information on
several types of parameters and across more than one
PICOS dimension (e.g. [30–32]). A full list of the included
papers along with a description of how information was
shared within each paper can be found in Additional file 3.
We also identified the most common synthesis chal-
lenges addressed by the included papers. Amongst papers
sharing information across populations, 3 [14, 55, 56]
developed models to accommodate simultaneous synthe-
sis of adult and paediatric evidence, 1 [33] described mod-
els that allowed information-sharing between patients
subgroups, and 2 [34, 54] provided model extensions for
baseline risk adjustment. Amongst papers sharing infor-
mation across interventions, 7 [35, 44–46, 51–53] simul-
taneously synthesised multiple dosages of the same treat-
ment, 7 [32, 33, 36, 44, 46, 49, 50] shared information
across interventions that fall under the same ‘class’, 5 [30,
36, 37, 47, 48] dealt with complex interventions (i.e. treat-
ments that comprise multiple components), and 4 [38–41]
described models on comparison-specific non-relative
effect parameters such as between-studies variances or
meta-regression slopes . Amongst papers sharing infor-
mation across study-designs, 9 [8, 85–89, 100–102] com-
bined randomised and non-randomised studies and 13
[42, 50, 85, 90–99] dealt with studies’ internal or exter-
nal biases. Amongst papers that shared information across
outcomes, 2 [31, 57] considered structurally related out-
comes (for instance, when one outcome has to occur
before the other), 6 [30, 45, 58, 59, 61, 79] combined
evidence from studies that reported at multiple/different
follow-up periods, and 34 papers [8, 25, 26, 30, 31, 57,
60, 62–78, 80–84, 102–106] considered correlated out-
comes. Finally, 7 papers described how evidence from
previous meta-analyses (meta-epidemiological evidence)
[24, 90, 107–109] or expert elicitation [68, 110] can be
incorporated in analyses.
‘Core’ relationships for information-sharing
The methods identified were classified according to the
‘core’ relationship facilitating information-sharing. Four
‘core‘ methods were identified: 1) functional relation-
ships which include deterministic functions among model
parameters resulting in a reduced number of parame-
ters that need to be estimated; 2) exchangeability-based
relationships which assume that a set of parameters are
drawn from a common distribution that allows them to
be shrunk towards its mean; 3) prior-based relation-
ships which employ a Bayesian framework to ‘load’ the
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Fig. 2 PRISMA diagram for search results
indirect evidence in prior distributions and 4) multi-
variate methods which assume that model parameters
are correlated and enable information-sharing through
the covariance structure. Figure 3 provides a description
of the main assumption and mathematical relationship
imposed by each ‘core’ method.
Table 1 classifies papers according to the ‘core’ method
used and the PICOS dimension of indirectness. It shows
that some ‘core’ relationships are preferred when infor-
mation is shared across specific PICOS dimensions.
For instance, most of the identified papers sharing
information across interventions either use functional
or exchangeability-based relationships, and no example
using priors was found. Also, papers that use multivari-
ate relationships, do so to share information across related
outcomes, not across populations or study-designs. This
may be partly because the information required to
implement multivariate methods for multiple popula-
tions or study-designs is usually unavailable in the lit-
erature. For instance, to synthesise evidence on multi-
ple populations using multivariate methods, we would
need studies that enrol all relevant populations and
report separately for each, and such information is rarely
provided.
Functional relationships
The simplest functional relationship is lumping (i.e. com-
mon effects) where all data points inform a single param-
eter independently of whether the evidence is direct or
indirect. Examples include pooling RTEs across time-
points [32], (sub-)populations [14, 33], or interventions of
the same treatment class [30, 32, 35, 36], as well as pooling
between-trial heterogeneity parameters [36, 39, 40, 43] or
meta-regression slopes [34, 38, 41].
Another type of functional relationship is a constraint
where a strict inequality is imposed among parameters.
In a Bayesian framework, information-sharing is facili-
tated by preventing simulation samples that do not con-
form to the specified constraint. Such methods have
been used to relate RTEs across dosages, expressing that
higher dosages are expected to exhibit larger RTE [35, 44],
describe structurally-related outcomes [57], and specify
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Table 1 A categorisation of papers that shared information according to the ‘core’ relationship that they used and the PICOS
dimension that direct and indirect evidence differ in
PICOS dimension of indirectness ‘Core‘ relationship
Functional Exchangeability based Prior-based Multivariate
Intervention Lumping: [30, 32–43] RE: [34, 38–42] SIP: No refs B: [36]
C: [35, 39, 40, 44] RW: [35] MixP: No refs W: No refs
L: [30, 35–38, 42, 45–48] MLM: [32, 33, 35, 44, 46, 49, 50] PP: No refs BW: No refs
N-L: [35, 51–53] S: No refs
Population Lumping: [14, 33] RE: [34, 54] SIP: [55] B: No refs
C: No refs RW: No refs MixP: [56] W: No refs
L: [33] MLM: [55] PP: [55] BW: No refs
N-L: No refs S: No refs
Outcomes Lumping: [32] RE: No refs SIP: No refs B: [30, 31, 57–60]
C: [57] RW: [45, 61] MixP: No refs W: [62]
L: [31] MLM: [30] PP: No refs BW: [26, 63–78]
N-L: [61, 79] S: [80–84]
Designs Lumping: No refs RE: No refs SIP: [85–90] B: No refs
C: No refs RW: No refs MixP: No refs W: No refs
L: [42, 50, 90–99] MLM: [85, 86, 88, 100] PP: [101] BW: No refs
N-L: No refs S: No refs
The ‘PICOS dimension of indirectness’ denotes the PICOS part (i.e. Population, Intervention etc.) on which the direct evidence differ from the indirect in terms of the research
question they address.
C: Constraint, L: Linear relationship (e.g. meta-regression), N-L: Non-linear, RE: Random-Effect, RW: Random-Walk, MLM: Multi-level model, SIP: Standard Informative Prior, MixP:
Mixture prior, PP: Power-prior, B: Only between-studies correlation modelled, W: Only within-study correlation modelled, B&W: Both within-study and between-studies
correlations modelled separately, S: Within-study and between-studies correlations modelled simultaneously as one parameter
second-order consistency equations that impose a trian-
gle inequality on the comparison-specific between-trial
variances [39, 40].
Meta-regression-type methods have also been sug-
gested. In the examples found, the relationships were
usually linear -on the modelling scale- with one RTE com-
ponent independent and another RTE component depen-
dent on a particular study characteristic. The most com-
mon example in this category is bias-adjustmentmethods,
primarily used to synthesise studies of different designs.
Bias-adjustment methods broadly fall into two categories:
general frameworks that adjust the RTE for biases affect-
ing internal and external validity provided that the extent
of bias can be either estimated from empirical evidence
or elicited from experts [91, 92, 98, 99], and approaches
that adjust for bias due to particular study-level char-
acteristics (considered proxies for study quality such as
their size [42, 50, 94–96], publication year [97], or risk-
of-bias [90, 93]). Meta-regression-type relationships have
also been used for complex interventions. In their simplest
form, they model the RTE of a complex intervention as
the sum of RTEs of its treatment components [30, 36, 47,
48]. More sophisticated approaches allow for synergistic
or antagonistic relationships by suggesting functions that
also contain treatment interaction RTE components [37].
Other applications include approaches that model the
RTEs for two survival outcomes (e.g. time-to-mortality
and time-to-progression) by assuming that they only dif-
fer by a constant component which is invariant across
treatment comparisons [31], models that assume a linear
relationship between dosage and RTE [35, 46], methods
for baseline-risk adjustment [34], and models that relate
the relative effects of populations subgroups of differing
disease severity [33].
Finally, more complex, non-linear, relationships have
also been presented in the literature, namely those
enabling the synthesis of RTEs across a range of dosages
using the Emax model [51–53] commonly employed in
pharmacokinetics or other non-linear models [35] and
those enabling information-sharing across follow-up peri-
ods [61, 79].
Exchangeability-based relationships
The simplest exchangeability-based relationship uses a
random effect to relate a set of parameters; in this
way accounting for heterogeneity without explicitly mod-
elling its source(s). The random effect assumes that
all parameters are drawn from a distribution, imply-
ing that individual parameters are shrunken towards the
random effect mean; this can happen to a greater or
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Fig. 3 ‘Core’ categories of information-sharing
lesser extent, depending on the precision and discrep-
ancy of each individual estimate in relation to the random
effect mean. Examples of parameters to which random-
effects have been applied include: comparison-specific
meta-regression slopes [34, 38, 41, 42, 50], comparison-
specific between-trial variances [39, 40], and study-
specific baseline-risks [34, 54].
Random-walks are another form of exchangeability rela-
tionship. They assume that data points which are more
similar with respect to a particular characteristic are
expected to exhibit more similar RTEs. Examples include
approaches assuming that the RTE of a particular dosage
or follow-up period is drawn from a distribution centred
around the RTE of its adjacently lower or higher dosage
[35] or follow-up period [45, 61].
Multi-level models also use exchangeability, but apply
it to the hierarchical/clustered structure of the available
data. As such, exchangeability is applied at a first level
within specific groups of parameters (i.e. multiple ran-
dom effects are applied, each within groups of RTEs
from studies showing a particular characteristic) and at a
second level across the group-specific hyper-parameters.
This is shown in Fig. 4, where in the bottom level, stud-
ies are categorised according to a characteristic and a
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Fig. 4 An illustration of a multi-level model
different random effect is imposed within every category,
producing group-specific basic parameters and hetero-
geneities. Subsequently, in the top-level, exchangeability
is also assumed across the group-specific basic parame-
ters which are shrunk towards an overall, global, group-
independent, hyper-mean. Examples include ‘class-effect’
models where, on top of the classical Random-Effects (RE)
NMA models, the basic parameters of treatments that
function through the same mechanism are assumed to
be drawn from a common distribution with an overall
‘class’ mean and an across-treatments, within-class, het-
erogeneity [32, 33, 35, 44, 46, 49]. Class-effect approaches
have also been imposed across comparison-specific meta-
regression slopes [38, 50]. Multi-level models have been
suggested to combine adult and paediatric evidence [55],
RTEs measured at different time-points [30], and studies
of different designs [85, 86, 88, 100].
Prior-based relationships
Direct and indirect evidence can also be combined
through the use of prior distributions. The process usually
consists of two-steps where initially the indirect evidence
is analysed and subsequently the resulting distribution is
used as a prior in the analysis of the direct evidence. Of
note is that this approach is mathematically equivalent to
lumping, which was described under functional relation-
ships. Examples include the combination of adult and pae-
diatric evidence [55] or randomised and non-randomised
evidence [85–89]. The prior can additionally be adjusted
for bias or its precision decreased [85]. Alternative ways to
define the prior include the use of meta-epidemiological
evidence or expert elicitation. The former has been used
primarily for bias-adjustment [90], whilst both the former
[24, 107, 108] and the latter [110] have been used to define
prior a distribution for the between-trials heterogeneity.
More nuanced prior-based approaches such as mixtures
of priors have also been used. Here, the informative prior
(distribution representing the indirect evidence) is not
used at face value, but instead mixed with a vague prior
according to weights that may be specified by the analyst
or estimated within the synthesis model. The resulting
informative prior is typically heavy-tailed, and allows
for ‘adaptive’ information-sharing whereby information-
sharing is stronger when the direct and indirect evidence
are in agreement and weaker when they conflict [56]. Mix-
tures of priors have been used to combine evidence on
RTE and between-studies heterogeneity across adults and
children [56] and to analyse the study-specific baseline
parameters from studies that enrol populations with dif-
ferent baseline risks [34]. The use of mixtures of priors has
also been discussed for the synthesis of randomised and
non-randomised evidence [85].
Finally, a flexible method that has been proposed is
the power-prior [111]. In this method, the likelihood of
the indirect evidence is raised to a power scalar 0 
a  1 which reflects the perceived similarity between
the two sources of evidence. When a = 1 the results are
equivalent to ‘lumping’ and when a = 0 results are iden-
tical to ‘splitting’. The power parameter, a, needs to be
specified, and it has been proposed to be elicited [112]
or varied in sensitivity analysis [113]. Power priors have
been used to combine observational and randomised evi-
dence [101] and for the synthesis of adult and paediatric
evidence [55].
Multivariate relationships
Multi-variate relationships have primarily been used to
share information across multiple outcomes. Multivariate
meta-analysis correlates the various outcomes and may
separate within- and between-studies correlations [73]. At
the within-study level, the study-specific correlations arise
due to differences among the included patients and indi-
cate how the outcomes co-vary across individuals within
the study. For example, patients who, due to a baseline
characteristic that makes their disease more severe, show
high values for outcome A, are also more likely to yield
high values for outcome B. At the between-studies level,
correlations arise mainly due to study-level differences
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such as the distribution of the patient-level characteristics
across studies. For instance, studies that enrol more severe
cases and therefore may show high values for the mean
of outcome A, are also more likely to result in high val-
ues for the mean of outcome B, whilst studies enrolling
less severe cases may show lower mean values for both
outcomes. These models can potentially produce more
precise estimates [75] and mitigate outcome reporting
bias [103, 104].
Multivariate methods have been developed to con-
sider two [74, 83, 84], three or more correlated out-
comes [26, 78], accommodate the simultaneous analyses
of multiple treatments [63, 68, 80], and assess the rela-
tionship between surrogate and final outcomes [65, 67].
Given that within-trial correlations are commonly not
reported, authors have suggested the use of external data
to inform these parameters [64] or, when external data is
not available, methods that approximate the within-study
co-variances [77]. Further extensions have been developed
to handle missing data [70], assist the estimation of the
between-studies covariance matrix when only a few stud-
ies are available [71], model the within-studies covariance
structure using copulas [72], and allow modelling of het-
erogeneity and inconsistency using two separate variance
components [69].
To accommodate cases where the within-trials correla-
tions are unavailable and cannot be otherwise obtained,
alternative methods, which require the same data as a
univariate approach and do not separate within- and
between-trials correlations have been suggested for MA
[81, 82] and NMA [80]. Assuming that the overall cor-
relation is not very strong, these methods perform very
similarly to their counterpart, which separates the two
correlations, whilst preserving their benefits against the
univariate approach.
Finally, some methods only account for either the
within- or the between- studies correlations. For exam-
ple, to model mutually exclusive outcomes, it has been
suggested to only account for the within-trials negative
correlations which are induced by the competing risks
structure of the data (i.e. the more patients that reach an
outcome, the fewer the patients that reach another out-
come) [62]. Also, other approaches have onlymodelled the
between-studies covariance matrix to allow simultaneous
synthesis of multiple outcomes [30, 31, 57, 60], accom-
modate outcomes reported at several follow-up periods
[58, 59] and enable information-sharing across different
treatment components of complex interventions [36].
Discussion
The aim of this review was to identify and classify evi-
dence synthesis methods that have been used to combine
evidence from sources that relate directly and indirectly to
a particular research question. A wide range of methods
have been developed to share information between pop-
ulations, treatments, outcomes and study-designs. We
found that across the breadth of methods identified,
four ‘core’ relationships are used to facilitate information-
sharing. These are functional, exchangeability-based,
prior-based, and multivariate relationships and are illus-
trated in Fig. 3.
This review highlights the breadth of methodological
options that can facilitate information-sharing. Although,
typically, particular relationships are used preferentially
to share information on specific information-sharing con-
texts, it is likely that several methods are applicable and
analysts would need to choose which method is more
appropriate. This paper highlights that appropriate con-
siderations need to bemade when choosing ‘core’ relation-
ships and methods because choices are likely to influence
the degree of information-sharing. Specifically, method
selection may be informed by the following consider-
ations; the first is the plausibility of the assumptions
imposed by the methods in the context of interest. By
classifying methods according to the ‘core‘ relationship
that enables information-sharing, we hope to facilitate a
clearer discussion about the plausibility of these assump-
tions in the decision context of interest.
The second is the degree of information-sharing that
is imposed between direct and indirect evidence. Within
the literature, there is limited exploration of how much
different methods borrow-strength from indirect evi-
dence, though for multivariate methods, it has been noted
that information-sharing is ‘usually modest’ [26, 66] and,
sometimes, instead of ‘borrowing-strength’, multi-variate
methods may end up ‘borrowing-weakness’ [114]. The
few studies that have assessed the degree of information-
sharing typically consider only the degree of precision
gains [115] rather than also examining how the point
estimate - which is also important for decision making
- changes. Further research to understand the extent to
which different methods share information is warranted.
Finally, decision-makers may be interested in explor-
ing different levels of information-sharing. One way to do
that is by using prior-based methods that allow some con-
trol on the degree of information-sharing. For instance, an
informative prior may use either the posterior distribution
of the mean, or the predictive distribution of the indirect
evidence. The former is equivalent to lumping, whilst the
latter imposes less information-sharing. Similarly, mix-
ture priors can regulate the weight that is placed on the
informative component, and power-priors allow a range
of values to be used for α which determines the extent of
information-sharing.
Whilst our literature search was systematic in its methods
and conduct, it is unlikely to have been fully comprehen-
sive. The use of citation-mining techniques, while efficient
and necessary for this search, may have missed relevant
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methods. This is because the sensitivity of citation-mining
methods depends on the existence and identification of
seminal papers [22] and on papers citing the most impact-
ful references [116]. Due to time lags in citations, this
technique may not capture recent developments within
a field [117]. We have also excluded methods developed
outside of health research and did not specifically target
the grey literature. Since the search was conducted, we
found in the grey literature a relevant method using multi-
variate methods to simultaneously synthesise the relative
effects of patients treated at different lines of treatment
[118]. However, we do not believe that the conclusions of
a comprehensive search (had it been possible) would dif-
fer from those in this paper, namely regarding the core
relationships identified, and the focus of sharing being on
sharing across outcomes and treatments. We would also
like to highlight that it would be important that further
research considers methods developed for different pur-
poses that could be applied for information sharing. One
example is commensurate priors which have been used
to combine individual-patient data and aggregate-level
evidence [119].
This paper is the first to summarise and categorise the
existing literature by classifying methods according to the
‘core’ assumption that they use to facilitate information-
sharing. Further research could explore the following
questions: first, how can we determine whether indirect
evidence is relevant? Second, how can the appropriate-
ness of each information-sharing method be assessed for
the synthesis problem at hand? Finally, can the extent
of information-sharing be quantified to assist transparent
decision-making?
Conclusions
We conclude that a plethora of methods has been used to
facilitate information-sharing. These can be categorised
according to the main assumption they impose into
functional, exchangeability-based, prior-based, and mul-
tivariate relationships. Despite the wide range of avail-
able methods, these are often used preferentially without
ensuring that all options have been explored. Given that
methods may differ in the degree of information-sharing
they impose, the implication is that the chosen method
may impose stronger or weaker information-sharing that
what is considered appropriate by policy-makers. Further
research should investigate ways of judging the appro-
priateness of the degree of information-sharing imposed
by each method, and assess the impact of using different
methods on decisions.
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